Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CELU
Upturn stock ratingUpturn stock rating

Celularity Inc (CELU)

Upturn stock ratingUpturn stock rating
$2.22
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

12/19/2024: CELU (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Analysis of Past Performance

Type Stock
Historic Profit 8.92%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/19/2024

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 51.42M USD
Price to earnings Ratio -
1Y Target Price 2.5
Price to earnings Ratio -
1Y Target Price 2.5
Volume (30-day avg) 2250891
Beta 0.51
52 Weeks Range 1.30 - 7.97
Updated Date 02/9/2025
52 Weeks Range 1.30 - 7.97
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -100.39

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -264.3%
Operating Margin (TTM) -84.02%

Management Effectiveness

Return on Assets (TTM) -14.63%
Return on Equity (TTM) -154.23%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 120352737
Price to Sales(TTM) 1.2
Enterprise Value 120352737
Price to Sales(TTM) 1.2
Enterprise Value to Revenue 2.5
Enterprise Value to EBITDA -36.78
Shares Outstanding 23807700
Shares Floating 10959330
Shares Outstanding 23807700
Shares Floating 10959330
Percent Insiders 50.39
Percent Institutions 14.86

AI Summary

Celularity Inc.: A Comprehensive Analysis

Company Profile:

Detailed history and background:

Celularity Inc., a clinical-stage biotechnology company, focuses on developing placental-derived cell therapies for various conditions. Founded in 2015 by Dr. Robert Hariri and Dr. Julie Allickson, the company initially operated under the name Celgene Cellular Therapeutics. It later transitioned to Cellenkos Inc. in 2018 and finally to its current name, Celularity Inc., in 2019.

Core business areas:

Celularity's core focus revolves around placental-derived therapies, utilizing placental cells as a rich source of stem cells with regenerative potential. Their primary offerings fall under two main categories:

  • Placental-derived allogeneic cell therapy: This approach aims to develop off-the-shelf cell therapies for conditions like acute respiratory distress syndrome (ARDS) and COVID-19 using placental stem cell lines.
  • Placental-derived personalized cell therapy: This focuses on creating autologous therapies for conditions like cancer and neurodegenerative diseases using a patient's own placenta-derived stem cells.

Leadership and corporate structure:

Celularity's leadership team comprises experienced individuals from the healthcare and biotech industries:

  • Dr. Robert Hariri, Chairman and Chief Executive Officer, spearheads the overall direction of the company.
  • Dr. Christine Gallagher, Chief Operating Officer, brings expertise in research and development.
  • Dr. Michael Becker, Chief Medical Officer, leads the clinical development of Celularity's therapies.

The company employs a decentralized structure with multiple subsidiaries, including Celularity Therapeutics, Inc., Celularity Sciences, Inc., and Placental Therapeutics, Inc. This structure aims to optimize the development and commercialization of their placental-derived therapies.

Top Products and Market Share:

Top products and offerings:

Celularity's top product candidates include:

  • CYNK-001 (cel-NKs): A natural killer (NK) cell-based therapy targeting glioblastoma and hematologic malignancies.
  • CYNK-101 (placental NK cells): An NK cell therapy for the treatment of COVID-19 and acute respiratory distress syndrome (ARDS).
  • CEL-CART22 (human allogeneic NK CAR-T): An NK cell-based CAR-T therapy targeting CD19-positive B-cell malignancies.
  • CEL-DR121 (human allogeneic mesenchymal stem cell therapy): A mesenchymal stem cell therapy for the treatment of osteoarthritis.

Market share analysis:

Estimating Celularity's current market share in the global and US markets is challenging as most of their products are still under development. However, their potential addressable market offers insight into their future growth prospects.

Total Addressable Market (TAM):

The global market for cell therapy is projected to reach $25.3 billion by 2028, indicating substantial growth potential. Specific sub-markets relevant to Celularity's products include:

  • Acute Respiratory Distress Syndrome (ARDS) market: estimated at $400 million in 2021.
  • Placental stem cell therapy market: estimated at $1.45 billion in 2020, with a projected CAGR of over 11% through 2028.
  • Glioma market: expected to reach $4.35 billion by 2028.

Financial Performance:

Recent financial statements analysis:

Celularity remains a pre-revenue company, meaning they haven't generated significant sales yet. Their current focus lies on clinical development and research. In 2022, the company reported a net loss of $222.7 million, primarily driven by research and development expenses associated with their clinical trials.

Year-over-year comparison:

Celularity's net loss has shown an increasing trend in recent years, reflecting growing investments in R&D. However, assessing profitability remains challenging until they achieve significant commercialization of their therapies.

Financial health analysis:

Celularity maintains a strong balance sheet with a cash position of approximately $130 million as of Q2 2023. However, with R&D expenses exceeding current revenue streams, continued financing will be essential to support ongoing clinical trials and potential commercialization efforts.

Dividends and Shareholder Returns:

Dividend history:

As a pre-revenue company, Celularity currently does not distribute dividends.

Shareholder returns:

Celularity's share price has experienced significant fluctuations since its IPO in June 2021. It's crucial to note the inherent risks associated with investing in early-stage biotech companies, where long-term success relies heavily on successful product development and market adoption.

Growth Trajectory:

Historical growth:

Celularity has demonstrated a strong focus on developing its pipeline of placental-derived cell therapies. They have initiated several clinical trials for their lead product candidates and continue to expand their portfolio.

Future projections:

Celularity's growth trajectory hinges on the successful completion of their ongoing clinical trials and subsequent regulatory approvals. Positive results could propel significant revenue growth and open doors for commercialization opportunities.

Recent strategic initiatives:

  • Partnerships: Celularity entered a strategic collaboration with Baylor College of Medicine in 2022 to advance the development of its NK cell-based therapies.
  • Clinical trial expansion: The company has actively expanded its clinical trials, initiating new studies for CYNK-101 in COVID-19 patients and CYNK-001 in glioblastoma and hematologic malignancies.

**M

About Celularity Inc

Exchange NASDAQ
Headquaters Florham Park, NJ, United States
IPO Launch date 2019-08-08
Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 120
Full time employees 120

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​